Successful outcomes following living donor liver transplantation for portopulmonary hypertension

Liver Transplantation

Volumn 16, Issue 8, 2010, Pages 983-989

  Bandara, Mahesh ^a,b   Gordon, Fredric D ^b,c   Sarwar, Akmal ^b,c   Knauft, M Elizabeth ^a,b   Pomfret, Elizabeth A ^b,c   Freeman, Richard B ^b,d,e   Wirth, Joel A ^a,b  

^a MAINE MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^d TUFTS MEDICAL CENTER   (United States)

^e DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVER ENZYME; PROSTACYCLIN; SILDENAFIL;

ADULT; ALCOHOLISM; ARTICLE; CASE REPORT; CIGARETTE SMOKING; CLINICAL FEATURE; DISEASE COURSE; ECHOCARDIOGRAPHY; FEMALE; HEART CATHETERIZATION; HEART HEMODYNAMICS; HEMOCHROMATOSIS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; ORGAN DONOR; PORTOPULMONARY HYPERTENSION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; FEMALE; GASTROENTEROLOGY; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; TISSUE AND ORGAN PROCUREMENT; TREATMENT OUTCOME;

EID: 77955687329     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22107     Document Type: Article

References (24)

1. Krowka MJ. Hepatopulmonary syndrome versus porto-pulmonary hypertension: distinctions and dilemmas. Hepatology 1997;25:1282-1284.
2. Yang YY, Lin HC, Lee WC, Hou MC, Lee FY, Chang FY, et al. Portopulmonary hypertension: distinctive hemodynamic and clinical manifestations. J Gastroenterol 2001;36:181-186.
3. Arcangeli C, Squillantini G, Santoro G, Marioni C, Forte P, Chibbaro G, et al. Association of pulmonary and portal hypertension. Minerva Cardioangiol 1996;44:343-352.
4. Swanson KL, Wiesner RH, Nyberg SL, Rosen CB, Krowka MJ. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant 2008;8:2445-2453.
5. Krowka MJ, Mandell MS, Ramsay MA, Kawut SM, Fallon MB, Manzarbeitia C, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 2004;10:174-182. (Pubitemid 38240114)
6. Krowka MJ. Portopulmonary hypertension and the issue of survival. Liver Transpl 2005;11:1026-1027.
7. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999;30:641-648. (Pubitemid 29409407)
8. Fix OK, Bass NM, De Marco T, Merriman RB. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol. Liver Transpl 2007;13:875-885.
9. Ashfaq M, Chinnakotla S, Rogers L, Ausloos K, Saadeh S, Klintmalm GB, et al. The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant 2007;7:1258-1264. (Pubitemid 46643089)
10. Sakai T, Planinsic RM, Mathier MA, de Vera ME, Venkataramanan R. Initial experience using continuous intravenous treprostinil to manage pulmonary arterial hypertension in patients with end-stage liver disease. Transpl Int 2009;22:554-561.
11. Austin MJ, McDougall NI, Wendon JA, Sizer E, Knisely AS, Rela M, et al. Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension. Liver Transpl 2008;14:287-291. (Pubitemid 351425480)
12. Gough MS, White RJ. Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension. Liver Transpl 2009;15:30-36.
13. Hemnes AR, Robbins IM. Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation. Liver Transpl 2009;15:15-19.
14. De Wolf AM, Scott VL, Gasior T, Kang Y. Pulmonary hypertension and liver transplantation. Anesthesiology 1993;78:213-214.
15. Mahapatra S, Nishimura RA, Sorajja P, Cha S, McGoon MD. Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J Am Coll Cardiol 2006;47:799-803. (Pubitemid 43243104)
16. Freise CE, Gillespie BW, Koffron AJ, Lok AS, Pruett TL, Emond JC, et al. Recipient morbidity after living and deceased donor liver transplantation: findings from the A2ALL Retrospective Cohort Study. Am J Transplant 2008;8:2569-2579.
17. Olthoff KM, Merion RM, Ghobrial RM, Abecassis MM, Fair JH, Fisher RA, et al. Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2ALL consortium. Ann Surg 2005;242:314-323.
18. Uchiyama H, Soejima Y, Taketomi A, Yoshizumi T, Harada N, Ijichi H, et al. Successful adult-to-adult living donor liver transplantation in a patient with moderate to severe portopulmonary hypertension. Liver Transpl 2006;12:481-484.
19. Rafanan AL, Maurer J, Mehta AC, Schilz R. Progressive portopulmonary hypertension after liver transplantation treated with epoprostenol. Chest 2000;118:1497-1500.
20. Mandell MS, Groves BM, Duke J. Progressive plexogenic pulmonary hypertension following liver transplantation. Transplantation 1995;59:1488-1490.
21. Prager MC, Cauldwell CA, Ascher NL, Roberts JP, Wolfe CL. Pulmonary hypertension associated with liver disease is not reversible after liver transplantation. Anesthesiology 1992;77:375-378.
22. Kett DH, Acosta RC, Campos MA, Rodriguez MJ, Quartin AA, Schein RM. Recurrent portopulmonary hypertension after liver transplantation: management with epoprostenol and resolution after retransplantation. Liver Transpl 2001;7:645-648. (Pubitemid 32677891)
23. Krowka MJ, Fallon MB, Mulligan DC, Gish RG. Model for End-Stage Liver Disease (MELD) exception for portopulmonary hypertension. Liver Transpl 2006;12(suppl):114S-116S.
24. Rodriguez-Luna H, Vargas HE, Moss A, Reddy KS, Freeman RB, Mulligan D. Regional variations in peer reviewed liver allocation under the MELD system. Am J Transplant 2005;5:2244-2247. (Pubitemid 41648472)